Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer clinical trial (NCT06221462). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to standard options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer clinical trial (NCT06221462). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of sintilimab and anlotinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer clinical trial (NCT06221462). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer clinical trial (NCT06221462). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the surgery after this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer clinical trial (NCT06221462). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer clinical trial (NCT06221462). Contact the study team or your healthcare provider for specific answers.

What this study is about